American Medical Systems' GreenLight HPSÃ‚® Approved for Use in Japan
MINNETONKA, Minn., May 4, 2011 /PRNewswire/ -- American Medical Systems® (AMS) (NASDAQ: AMMD), a leading provider of world-class devices and therapies for male and female pelvic health, today announced it has received clearance from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market and distribute its GreenLight HPS® laser therapy system for the treatment of Benign Prostatic Hyperplasia (BPH), or enlarged prostate, in Japan.
As the worldwide market leader in laser BPH treatment, AMS' GreenLight provides treatment with fewer side effects than TURP, improving clinical outcomes and patient safety for individuals with mild to severe BPH symptoms. The system is designed to enable the treatment of a wide range of gland sizes, as well as for patients on anti-coagulation therapy.
"We are thrilled to offer this leading-edge technology to provide a safer and less-invasive BPH treatment for Japanese men," said Mike Ryan, AMS' vice president and general manager for Asia Pacific, Latin America and Canada. "The approval of GreenLight represents a significant opportunity in Japan, as BPH is one of the most common diseases among older Japanese men, with the number of treatment procedures growing by over 4 percent each year."
GreenLight's high performance system (HPS) delivers efficient procedure times and the ability to treat large glands. The system will be offered in Japan through an exclusive distribution agreement with MC Medical, Inc., a subsidiary of Mitsubishi Corporation and a leading supplier of minimally invasive medical devices and supplies in Japan.
"Over 500,000 patients worldwide have been treated with GreenLight and with nearly 4 million men suffering from moderate to severe BPH symptoms in Japan, this is a great opportunity for us to help a growing population," Ryan said. "Not only does this expansion strengthen AMS' global presence but it also all